Humacyte, Inc. Warrant (expiring August 27, 2026)

Humacyte Inc. is a biotechnology company that focuses on developing bioengineered human tissues and organs aimed at significantly improving patient care and outcomes. Its primary function is to create and commercialize off-the-shelf, universally implantable human tissue solutions. The company's proprietary technology platform allows it to produce durable, human acellular blood vessels (HAVs), which have potential applications in a variety of vascular surgeries and treatments, ranging from peripheral arterial disease to vascular trauma. Humacyte Inc.'s products are designed to integrate with the patient's own tissue, promoting long-term performance and reducing the risk of complications commonly associated with traditional graft methods. Operating within the broader healthcare and life sciences sector, Humacyte's innovations have far-reaching implications, offering solutions that may address significant unmet medical needs. By leveraging advancements in regenerative medicine, Humacyte plays a key role in pioneering next-generation medical technologies that aim to enhance the quality of life for patients globally.